Outpatient percutaneous coronary interventions: hospital and health system costs saving while maintaining patient safety

JACC Cardiovasc Interv. 2010 Oct;3(10):1020-1. doi: 10.1016/j.jcin.2010.09.001.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Abciximab
  • Acute Coronary Syndrome / economics
  • Acute Coronary Syndrome / therapy*
  • Ambulatory Care / economics
  • Angioplasty, Balloon, Coronary / adverse effects
  • Angioplasty, Balloon, Coronary / economics
  • Angioplasty, Balloon, Coronary / instrumentation
  • Angioplasty, Balloon, Coronary / methods*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / economics
  • Cost Savings
  • Cost-Benefit Analysis
  • Drug Costs
  • Health Care Costs*
  • Hospital Costs
  • Humans
  • Immunoglobulin Fab Fragments / administration & dosage*
  • Immunoglobulin Fab Fragments / economics
  • Length of Stay
  • Patient Discharge / economics
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / economics
  • Radial Artery*
  • Stents
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Abciximab